Vistagen Therapeutics sued for securities fraud in class action lawsuit.

Vistagen Therapeutics faces a class action lawsuit for alleged securities violations. The lawsuit claims the company misled investors about the results of its PALISADE-2 trial of fasedienol, creating a false impression that its drug candidate would succeed in Phase 3 trials. Shareholders who purchased VTGN shares during the class period (April 1, 2024 to December 16, 2025) are encouraged to contact the firm regarding possible lead plaintiff appointments.